Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma

• DOI: 10.1200/jco.2012.45.3308
• Publication Date: 2012-12-18T05:41:57Z
• Authors: Alison J. Moskowitz; Paul A. Hamlin; Miguel-Angel Perales; John Gerecitano; Steven M. Horwitz; Matthew J. Matasar; Ariela Noy; Maria Lia Palomba; Carol S. Portlock; David J. Straus; Tricia Graustein; Andrew D. Zelenetz; Craig H. Moskowitz
• Keywords: Bendamustine; Refractory (planetary science); Autologous stem-cell transplantation; Salvage therapy; Clinical endpoint

Limited data exist regarding the activity of bendamustine in Hodgkin lymphoma (HL). This phase II study evaluated efficacy relapsed and refractory HL.Patients with HL who were ineligible for autologous stem-cell transplantation (ASCT), or whom this treatment failed, received 120 mg/m(2) as a 30-minute infusion on days 1 2 every 28 growth factor support. The primary end point was overall response rate (ORR). A secondary referral to allogeneic (alloSCT) patients deemed eligible alloSCT at time enrollment.Of 36 enrolled, 34 evaluable response. Patients had median four prior treatments, 75% after ASCT. ORR by intent-to-treat analysis 53%, including 12 complete responses (33%) seven partial (19%). among 56%. Responses seen disease, ASCT, alloSCT; however, no within 3 months duration 5 months. Five (20% those eligible) proceeded bendamustine. Grade ≥ adverse events infrequent most commonly included thrombocytopenia (20%), anemia (14%), infection (14%).This confirms heavily pretreated HL. These results support current future studies evaluating combinations